Sangamo Therapeutics, Inc. announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities.

Dr. Rojkjaer brings over 20 years of global and regional clinical development, regulatory, and medical affairs experience, as well as an international clinical practice background. She has held several senior leadership positions in both clinical development and medical affairs in biotech and global pharmaceutical companies, having most recently served as Chief Medical Officer at Viracta Therapeutics. She previously served in several senior positions focused on the development of small molecules and biologics for hematology and immunology indications, including Chief Medical Officer at Nordic Nanovector.

Dr. Rojkjaer was the Global Clinical Program Head at Novartis Oncology, where she led development and supported the regulatory approval of Rydapt®. Other previous roles include Chief Medical Officer at Molecular Partners, and VP, Head of Clinical Development at MorphoSys AG. Earlier, at Novo Nordisk, she served as Director of Clinical Development, Hematology in the US and Head, Global Medical Affairs, Biopharmaceuticals while based in Denmark.

Dr. Rojkjaer holds a Doctor of Medicine degree from the University of Toronto, where she also completed her internal medicine and hematology fellowships.